



This clinical research study is evaluating an investigational vaccine in the prevention of a bloodstream infection caused by a bacteria called *E. coli*.

The purpose of the E.mbrace Study is to determine if the investigational vaccine is safe and effective.

What will happen during the clinical study?

In this study, participants who are eligible will be randomly assigned to receive either the investigational vaccine or placebo, given as a single injection. A placebo vaccine contains no active drug but will look exactly like the investigational vaccine. Total participation in this study will last approximately 3 years, which includes a minimum of 8 study visits, some in person and some remote via telephone.

The importance of diversity in clinical research studies

Research has shown that certain diseases, treatments and medications may impact people differently based on their age, gender and genetic background, including race and ethnicity. It is important to conduct research studies with diverse populations to help ensure that vaccines and medications are generally safe and effective (or the benefits outweigh the risks).

To be eligible for this study, you must:

- Be 60 years of age or older
- Have had a urinary tract infection (UTI) in the past 2 years
- Feel comfortable, or have a caregiver who is comfortable using an application on a smartphone

Qualified participants may receive the investigational vaccine or placebo and some study-required medical care at no cost.

If you are interested in learning more about the E.mbrace Study, please contact the Church street practice research team on bobicb-ox.churchstreet.research@nhs.net.

Yours sincerely,

Dr. Matthew Gaw; Partner and Principal Investigator; Church Street Practice

www.EmbraceVaccineStudy.com